Table 3.
Effects of various long-term dosing regimens of Hiltonol® at day 3 post virus exposure on various lung parameters in BALB/c mice infected with SARS-CoV.
| Treatment | Virus titer (Log10CCID50/g) ± SD | Virus Lung Score ± SD | Lung Weight (g) ± SD |
|---|---|---|---|
| Treatment Day -21 | |||
| PSS | 6.11 ± 0.41 | 2.1 ± 0.5 | 0.28 ± 0.02 |
| Hiltonol® (2.5 mg/kg/day) | 5.50 ± 0.39 | 0.3 ± 0.3* | 0.21 ± 0.03* |
| Hiltonol® (0.75 mg/kg/day) | 5.58 ± 0.30 | 0.4 ± 0.5 | 0.31 ± 0.03 |
| Treatment Day −14 | |||
| PSS | 5.76 ± 0.43 | 3.7 ± 0.3 | 0.34 ± 0.03 |
| Hiltonol® (2.5 mg/kg/day) | 4.95 ± 0.56** | 0.0 ± 0.0* | 0.20 ± 0.02** |
| Hiltonol® (0.75 mg/kg/day) | 6.04 ± 0.38 | 0.5 ± 0.0* | 0.24 ± 0.04 |
| Treatment Day -7 | |||
| PSS | 5.94 ± 0.34 | 3.4 ± 1.0 | 0.34 ± 0.05 |
| Hiltonol® (2.5 mg/kg/day) | 5.58 ± 0.65 | 0.0 ± 0.0* | 0.22 ± 0.02* |
| Hiltonol® (0.75 mg/kg/day) | 6.05 ± 0.27 | 0.4 ± 0.4 | 0.21 ± 0.04** |
| Ampligen® (10 mg/kg/day) bid x 2, beg −4 h | 6.49 ± 0.31 | 1.2 ± 1.4 | 0.26 ± 0.1 |
*p < 0.05, **p < 0.01 compared to PSS control.